Purpose
Postoperative nausea and vomiting (PONV) are commonly observed undesirable consequences of laparoscopic cholecystectomy. This study was undertaken to compare granisetron, a selective 5-hydroxytryptamine type 3 receptor antagonist, with dropendol for reducing the incidence and seventy of PONV after laparoscopic cholecystectomy.
Methods
Eighty patients, aged 25–65 yr. scheduled for elective laparoscopic cholecystectomy were enrolled in a randomized, double-blinded investigation and assigned to one of three treatment regimens: placebo (saline), 1.25 mg dropendol (approximately 25μg·kg−1) or 3 mg granisetron (approximately 60μg·kg−1). The study drugs were administerediv immediately before the induction of anaesthesia. A standard general anaesthetic technique was employed throughout. Nausea, vomiting and safety assessments were performed continuously dunng the first 24 hr after anaesthesia.
Results
The incidence of PONV was 46% with placebo, 41 % with dropendol and 15% with granisetron (P< 0.05; overall C2 test). Four patients who had received placebo and two who had received dropendol required another rescue antiemetic, compared with none who had received granisetron (P< 0.05). Adverse events postoperatively were not different among the groups.
Conclusion
Granisetron is more effective than dropendol and placebo for reducing the incidence and seventy of PONV after laparoscopic cholecystectomy.